Biohope is a commercial stage biomedical company focused in the R&D of PRECISION MEDICINE IVD tools, to improve clinical outcomes in patients with chronic inflammatory conditions and autoimmune diseases. Biohope has developed an IVD kit called Immunobiogram® to facilitate a personalized drug treatment for patients with chronic inflammatory diseases. The first product, for patients with a kidney transplant, has shown positive results in our Clinical Studies. Immmunobiogram® is: A unique and innovative product without competition on the market. It addresses a huge unmet medical need (out of +1 million patients in the world, 50% will reject the organ in less than 10 years). Non-optimal medication accounts for a large proportion of graft rejection. It provides, the level of sensitivity of the patient immune cells to immunosuppressive drugs in order to facilitate a personalized treatment to improve clinical outcomes. In only 6 years BIOHOPE is prepared to launch its first product to the market, after successfully studied the Immunobiogram® for kidney transplantation in international clinical studies with main hospitals from Europe and USA. BIOHOPE has met all the planned milestones so far, confirming it’s a reliable and promising company. Relevant facts: Unique software and database of patient’s T lymphocyte response. Patents published, and registered trademark in main markets. CE mark for first product in kidney transplantation, expected registration in Americas in 2021/2022. License for manufacturing. BIOHOPE’s objective is to support physicians by providing them with tools to optimize and personalize treatments (precision medicine) and thus improve the response and quality of life of patients. To achieve this goal, a strong pipeline in autoimmune diseases is planned. The core values of BIOHOPE are Ethics, Results Orientation, Innovation, Adaptation, and Continuous Learning. We seek to maintain open, honest and frequent communication with our Stakeholders.